Summarized by Masters of Longevity from Longevity Technology.
Report on new mechanistic data showing an ALS drug candidate targets a specific mitochondrial protein to prevent damaging pore opening and protect neurons.
Key Takeaways
- NRG Therapeutics identified NLRX1 as the mitochondrial protein that controls mPTP opening in their ALS model.
- In mouse ALS models, NRG5051 reduced neuroinflammation and lowered plasma neurofilament light chain levels.
- NRG5051 is in a Phase 1 healthy volunteer trial with patient dosing planned before year-end and Phase 2 planned for 2027.
